Skip to main content
. 2007 Oct;9(10):797–800. doi: 10.1593/neo.07595

Table 2.

Tumor Characteristics and Association with Per1 Expression Levels (N = 33).

Characteristic Low Per1 Levels (≤ 1.60) High Per1 Levels (> 1.60) P* (Fisher's Exact Test)
Number of patients [n (%)] 20 (60.6) 13 (39.4)
Age (years) {mean (SD) [minimum, maximum]} 55.2 (11.5) [35.1, 75.1] 55.2 (11.7) [37.5, 69.7]
Menopausal status [n (%)]
Premenopausal 6 (30.0) 4 (30.8) 1.00
Perimenopausal 2 (10.0) 1 (7.7)
Postmenopausal 11 (55.0) 8 (61.5)
Missing 1 (5.0) 0 (0.0)
Maximum size of tumor (cm) [n (%)]
0.5 to < 1.0 0 (0.0) 0 (0.0) .06
1.0 to < 2.0 2 (10.0) 4 (30.8)
2.0 to < 5.0 17 (85.0) 7 (53.8)
≥ 5.0 0 (0.0) 2 (15.4)
Missing 1 (5.0) 0 (0.0)
ER status
Positive 9 (45.0) 9 (69.2) .04
Negative 10 (50.0) 2 (15.4)
Equivocal 0 (0.0) 2 (15.4)
Unknown/not determined 0 (0.0) 0 (0.0)
Missing 1 (5.0) 0 (0.0)
Progesterone receptor status
Positive 5 (25.0) 5 (38.5) .86
Negative 12 (60.0) 7 (53.8)
Equivocal 2 (10.0) 1 (7.7)
Unknown/not determined 0 (0.0) 0 (0.0)
Missing 1 (5.0) 0 (0.0)
Histologic grade
1 1 (5.0) 1 (7.7) .90
2 6 (30.0) 5 (38.5)
3 9 (45.0) 4 (30.8)
Subtype 1 (5.0) 0 (0.0)
Unknown/not determined 2 (10.0) 3 (23.0)
Missing 1 (5.0) 0 (0.0)
Lymphatic invasion
Yes 5 (25.0) 5 (38.5) .70
No 14 (70.0) 8 (61.5)
Missing 1 (5.0) 0 (0.0)
*

Without tumors in the missing category.

HHS Vulnerability Disclosure